Tumor immunotherapy: Cytokines and antigen presentation

Cancer Immunology Immunotherapy

Volumn 46, Issue 2, 1998, Pages 75-81

  Lord, Edith M ^a   Frelinger, John G ^a  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

Author keywords

Antigen presentation Immunotherapy; Cytokines; Cytolytic T lymphocytes

Indexed keywords

B7 ANTIGEN; CD4 ANTIGEN; CD8 ANTIGEN; CYTOKINE; FLUCYTOSINE; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; TRANSFORMING GROWTH FACTOR BETA; TUMOR ANTIGEN; TUMOR VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIGEN PRESENTING CELL; CANCER IMMUNOLOGY; CANCER IMMUNOTHERAPY; CELL GROWTH; CONFERENCE PAPER; CYTOTOXIC T LYMPHOCYTE; GROWTH INHIBITION; HUMAN; HUMAN CELL; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION; TUMOR CELL;

ANIMALS; ANTIGEN PRESENTATION; ANTIGEN-PRESENTING CELLS; CYTOKINES; HUMANS; LYMPH NODES; NEOPLASMS; T-LYMPHOCYTES;

EID: 0031978702     PISSN: 03407004     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002620050464     Document Type: Conference Paper

References (46)

1. Allison JP, Hurwitz AA, Leach DR (1995) Manipulation of costimulatory signals to enhance antitumor T-cell response. Curr Opin Immunol 7:682
2. Austyn JM (1996) New insights into the mobilization and phagocytic activity of dendritic cells. J Exp Med 183:1287
3. + tumor cells are potent vaccines for stimulating tumor rejection in tumor-bearing mice. J Exp Med 181:619
4. + T cell help. J Exp Med 186:65
5. Bevan MJ (1976) Cross-priming for a secondary cytotoxic response to minor H antigens with H-2 congenic cells which do not cross-react in the cytotoxic assay. J Exp Med 143:1283
6. + hematopoietic progenitors from human cord blood differentiate along two independent dendritic-cell pathways in response to GM-CSF+TNFα. J Exp Med 184:695
7. Celluzi CM, Mayordomo JI, Storkus WJ, Lotze MT, Falo LD (1996) Peptide pulsed dendritic cells induce antigen-specific CTL-mediated protective tumor immunity. J Exp Med 183:283
8. Chaux P, Hammann A, Martin F, Martin M (1993) Surface phenotype and functions of tumor-infiltrating dendritic cells: CD8 expression by a cell subpopulation. Eur J Immunol 23:2517
9. Chaux P, Martin MS, Martin F (1996) T-cell co-stimulation by the CD28 ligand B7 is involved in the immune response leading to rejection of a spontaneously regressive tumor. Int J Cancer 66:244
10. Chen L, McGowan P, Ashe S, Johnston HJ, Li Y, Hellstrom I, Hellstrom KE. (1994) Tumor immunogenicity determines the effect of B7 costimulalion on T cell-mediated tumor immunity. J Exp Med 179:523
11. Dranoff G, Jaffee E, Lazenby A, Golumbek P, Levitsky H, Brose K, Jackson V, Hamada H, Pardoll D, Mulligan RC (1993) Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc Natl Acad Sci USA 90:3539
12. Feltkamp MCW, Smits HL, Vierboom MPM, Minnaar RP, De Jongh BM, Drijfhout JW, Ter Schegget J, Melief CJM, Kast WM (1993) Vaccination with cytotoxic T lymphocyte epitope-containing peptide protects against a tumor induced by human papillomavirus type 16-transformed cells. Eur J Immunol 23:2242
13. Folkman J, Shing Y (1992) Angiogenesis. J Biol Chem 267:10931
14. Gooding LR, Edwards CB (1980) H-2 antigen requirements in the in vitro induction of SV40-specific cytotoxic T lymphocytes. J Immunol 124:1258
15. + CTLs in the absence of exogenous help. J Exp Med 177:1791
16. Huang AYC, Golumbek P, Ahmadzadeh M, Jaffee E, Pardoll D, Levitsky H (1994) Role of bone marrow-derived cells in presenting MHC class I-restricted tumor antigens. Science 264:961
17. Huang AY, Bruce AT, Pardoll DM, Levitsky HI (1996) Does B7-1 expression confer antigen-presenting cell capacity to tumors in vivo? J Exp Med 183:769
18. Kerrebijn JD, Balm AJ, Knegt PP, Meeuwis CA, Drexhage HA (1994) Macrophage and dendritic cell infiltration in head and neck squamous-cell carcinoma: an immunohistochemical study. Cancer Immunol Immunother 38:31
19. Kovacsovics-Bankowski M, Clark K, Benacerraf B, Rock KL (1993) Efficient major histocompatibility complex class I presentation of exogenous antigen upon phagocytosis by macrophages. Proc Natl Acad Sci USA 90:4942
20. Lee J, Fenton BM, Koch CJ, Frelinger JG, Lord EM (1998) Interleukin-2 expression by tumor cells alters both the immune response and the tumor microenvironment. Cancer Res (in press)
21. Letterio JJ, Roberts AB (1996) Transforming growth factor-beta 1-deficient mice: identification of isoform-specific activities in vivo. J Leukoc Biol 59:769
22. + T lymphocytes by B7, a natural ligand for CD28 can be used to treat established mouse melanoma. J Immunol 153:421
23. Loeffler D., Keng PC, Baggs B, Lord EM (1990) Lymphocytic infiltration and cytotoxicity under hypoxic conditions in the EMT6 mouse mammary tumor. Int J Cancer 45:462
24. Lord EM, Yeh K-Y, Moran JP, Storozynsky E, Frelinger JG (1997) IL-3 mediated enhancement of particulate antigen presentation by macrophages. J Immunother (in press)
25. Mandelboim O, Vadai D, Fridkin M, Katz-Hillel A, Feldman M, Berke G, Eisenbach L (1995) Regression of established murine carcinoma metastases following vaccination with tumour-associated antigen peptides. Nat Med 1:1179
26. Marchand M, Wegmants P, Rankin E, Arienti F, Beli F, Parmiani G, Cascineli N, Bourland A, VanWijck R, Humblet Y (1995) Tumor regression responses in melanoma patients treated with a peptide encoded by gene MAGE-3. Int J Cancer 63:883
27. Massague J (1990) The transforming growth factor-β family. Annu Rev Cell Biol 6:597
28. Mattei S, Colombo MP, Melani C, Silvani A, Parmiania G, Herlyn M (1994) Expression of cytokine/growth factors and their receptors in human melanoma and melanocytes. Int J Cancer 56:853
29. McAdam AJ, Felcher A, Woods ML, Pulaski BA, Hutter EK, Frelinger JG, and Lord EM (1994) Transfection of transforming growth factor-β producing tumor EMT6 with interleukin-2 elicits tumor rejection and tumor reactive cytotoxic T-lymphocytes. J Immunother 15:155
30. McAdam AJ, Pulaski BA, Storozynsky E, Yeh K-Y, Sickel JZ, Frelinger JG, Lord EM (1995) Analysis of the effect of cytokines (interleukins 2,3,4, and 6, granulocyle-monocyte colony-stimulating factor, and interferon-γ) on generation of primary cytotoxic T lymphocytes against a weakly immunogenic tumor. Cell Immunol 165:183
31. Musiani P, Modesti A, Giovarelli M, Cavallo, F, Colombo M, Lollini PL, Forni G (1997) Cytokines, tumour-cell death and immunogenicity: a question of choice. Immunol Today 18:32
32. Norbury CC Hewlett LJ, Prescott AR, Shastri N, Watts C (1995) Class I MHC presentation of exogenous soluble antigen via macropinocytosis in bone marrow macrophages. Immunity 3:783
33. Peters JH, Gieseler R, Thiele B, Steinbach F (1996) Dendritic-cells: from ontogenetic orphans to myelomonocytic descendants. Immunol Today 17:273
34. Pfeifer JD, Wick MJ, Roberts RL, Fidlay K, Normark SJ, Harding CV (1993) Phagocytic processing of bacterial antigens for class I MHC presentation to T cells. Nature 361:359
35. Pulaski BA, McAdam AJ, Hutter EK, Biggar S, Lord EM, Frelinger JG (1993) IL-3 transfection enhances development of tumor reactive cytotoxic cells by a CD4 dependent mechanism. Cancer Res 53:2112
36. Pulaski BA, Yeh K-Y, Shastri N., Maltby K, Penney DP, Lord EM, Frelinger JG (1996) Interleukin 3 enhances cytotoxic T lymphocyte development and class I major histocompatibility complex "re-presentation" of exogenous antigen by tumor-infiltrating antigen-presenting cells. Proc Natl Acad Sci USA 93:3669
37. Rock KL (1996) A new foreign policy: MHC class I molecules monitor the outside world. Immunol Today 17:131
38. Salluslo F, Cella M, Danieli C, Lanzavecchia A (1995) Dendritic cells use macropinocytosis and the mannose receptor to concentrate macromolecules in the major histocompatibility complex class II compartment: down regulation by cytokines and bacterial products. J Exp Med 182:389
39. Steinman RM (1991) The dendritic cell system and its role in immunogenicily. Annu Rev Immunol 9:271
40. Suss G, Shortman K (1996) A subclass of dendritic cells kills CD4 T cells via Fas/Fas ligand-induced apoptosis. J Exp Med 183:1789
41. Szabolcs P, Avigan D, Gezelter S, Ciocon DH, Moore MAS, Steinman RM, Young JW (1996) Dendritic cells and macrophages can mature independently from a human bone marrow-derived, post-colony-forming unit intermediate. Blood 87:4520
42. Thurnher M, Radmayr C, Ramoner R, Ebner S, Bock G, Klocker H, Romani N, Bartsch G (1996) Human renal-cell carcinoma tissue contains dendritic cells. Int J Cancer 68:1
43. Toes REM, Blom RJJ, Offringa R, Kast WM, Melief CJM (1996) Functional deletion of tumor-specific CTLs induced by peptide vaccination can lead to the inability to reject tumours. J Immunol 156:3911
44. Van Pel A, Van der Bruggen P, Coulie PG, Brichard VG, Lethe B, Van der Eynde B, Uyttenhove C, Renauld J-C, Boon T (1995) Genes coding for tumor antigens recognized by cytolytic T lymphocytes. Immunol Rev 145:229
45. Yeh K-Y, Pulaski BA, Woods, ML, McAdam, AJ, Gaspari AA, Frelinger JG, Lord EM (1995) B7-1 enhances natural killer cell-mediated cytotoxicity and inhibits tumor growth of a poorly immunogenic murine carcinoma. Cell Immunol 165:217
46. Zinkernagel RM, Ehl, S, Aichele, P, Gehen S, Kundig T, Hengartner H (1997) Antigen localization regulates immune responses in a dose- and time-dependent fashion: a geographical view of immune reactivity. Immunol Rev 156:199